Program
Gonadotropin-Releasing Hormone
Also written as “GnRH iontophoretic transdermal Lutrepatch”, “Luteinizing Hormone-Releasing Hormone (LHRH) Agonists” and “Lutrepulse”.
Its studies are mostly in Amenorrhea · Infertility · Ovarian Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ferring Pharmaceuticals | 40 open or running | phase 3since Feb 23, 2006 | Feb 23, 2006 | none ahead |
| Hoffmann-La Roche | 11 open or running | phase 2since Jun 9, 2021 | Jun 9, 2021 | Feb 28, 2028phase 2 · NCT04931342 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 23, 2006First study: phase 3 study in InfertilityNew to Ferring PharmaceuticalsFerring Pharmaceuticals · NCT00296465 · 132 enrolled · United States
- Nov 20, 2008Phase 2 study in InfertilityFerring Pharmaceuticals · NCT00796289 · 350 enrolled · United States
- Oct 15, 2013Phase 3 study in Primary Amenorrhea With Hypogonadotropic HypogonadismFerring Pharmaceuticals · NCT01976728 · 39 enrolled · United States, Canada
- Jun 9, 2021Hoffmann-La Roche’s first study: phase 2 study in Ovarian NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT04931342 · 176 enrolled · United States, Australia, Canada and more
- Aug 26, 2025Phase 1 study in AmenorrheaFerring Pharmaceuticals · NCT07152730 · United States
Ahead
- Feb 28, 2028Primary completion: phase 2 study in Ovarian NeoplasmsHoffmann-La Roche · NCT04931342
TargetBeta
“Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule
Other programs on GNRHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Leuproliderule | Takeda | phase 4 | 39 |
| triptorelinrule | Ipsen | phase 4 | 21 |
| Goserelinrule | AstraZeneca | phase 4 | 14 |
| linzagolixrule | Kissei Pharmaceutical | phase 3 | 14 |
| GnRH Antagonist SHR7280 | Jiangsu HengRui Medicine | phase 3 | 10 |
| leuprolide mesylaterule | foresee-pharmaceuticals-co-ltd | phase 3 | 3 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07152730Amenorrhea · United States | 1 | Withdrawn | Ferring Pharmaceuticals | Oct 29, 2025 | 0 |
| NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Hoffmann-La Roche | Feb 28, 2028 | 176 |
| NCT01976728Primary Amenorrhea With Hypogonadotropic Hypogonadism · United States, Canada | 3 | Completed | Ferring Pharmaceuticals | Feb 23, 2018 | 39 |
| NCT00796289Infertility · United States | 2 | Completed | Ferring Pharmaceuticals | Dec 2009 | 350 |
| NCT00296465Infertility · United States | 3 | Completed | Ferring Pharmaceuticals | Nov 2005 | 132 |
How it is read
Names in the registry
- “GnRH iontophoretic transdermal Lutrepatch”, 3 entries
- “Luteinizing Hormone-Releasing Hormone (LHRH) Agonists”, 1 entry
- “Lutrepulse”, 1 entry
- “Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump”, 1 entry
- “Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump”, 1 entry
Conditions, from the studies’ own filings
- Amenorrhea, 2 studies
- Infertility, 2 studies
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.